| |
MESSAGE _ENGLISH VERSION_ |
|
| |
Current report no. 46/2026 Date: 19 November 2026 Subject: Selection of Andelyn Biosciences, Inc. as manufacturer of the AAV5 vector for the Huntington's disease gene therapy program and execution of an agreement for the first phase of work Legal basis: Article 17_1_ MAR - inside information Content of the report: The Management Board of multiQure S.A., with its registered office in Wrocław _the "Company"_, announces that on 17 November 2026 it resolved to select Andelyn Biosciences, Inc., with its registered office in Columbus, Ohio, USA _"Andelyn"_, as the contract development and manufacturing organization _CDMO_ for the AAV5 vector carrying the Company's RNAi expression cassette, developed in the Company's Huntington's disease gene therapy program _the "MQ-201 Program"_. Andelyn is to be responsible for manufacturing the plasmids and the AAV5 vector under GMP for the planned clinical trial, under separate agreements that are currently being negotiated. On 18 November 2026, the Company entered into an agreement with Andelyn covering the first phase of work _the "Agreement"_. The Agreement covers: 1. development of a genomic titer method for the vector, specific to the Company's cassette, 2. synthesis and cloning of the plasmid carrying the Company's cassette, and its research-grade production, 3. optimization of the upstream and downstream vector manufacturing process, 4. production of a research-grade AAV5 vector batch in a 50 L bioreactor. The work will be performed on Andelyn's manufacturing platform based on suspension HEK293 cell culture, which is also intended for GMP production. Material produced under the Agreement is intended for development work and preclinical studies and will not be used in humans. The estimated duration of the work is approximately 8 months from the purchase order. Andelyn's fee under the Agreement is USD 376,500 net _approx. PLN 1,506,828.30 at the National Bank of Poland average exchange rate of 17 November 2026_, payable in stages, of which USD 174,000 _approx. PLN 696,382.80_ is due upon execution of the Agreement. Under the Agreement, the Company has undertaken that Andelyn will be its partner for subsequent statements of work leading to the manufacture of GMP clinical material, unless precluded by regulatory, technical or financial factors. In parallel, the Company and Andelyn are negotiating a Master Services Agreement _"MSA"_ under which statements of work for GMP manufacturing will be executed. As of the date of this report, neither the MSA nor the GMP statement of work has been executed. Their execution requires agreement on the remaining terms, including those relating to the parties' liability and licences to Andelyn's technologies. The Company will announce the execution of the MSA and the GMP statement of work in a separate report. The other terms of the Agreement do not differ from terms commonly used in agreements of this kind. Andelyn is a contract manufacturer specializing in the development and manufacture of viral vectors for gene therapies, including clinical trial material. According to Andelyn, it has more than 20 years of experience, has produced cGMP material for more than 500 clinical batches and 80 clinical trials worldwide, and its manufacturing facility in Columbus _Ohio, USA_ has successfully completed an FDA Pre-License Inspection and EU Qualified Person _QP_ audits. The Management Board considered the above information to be inside information because the selection of the clinical material manufacturer determines the further timeline of the MQ-201 Program, the Company's main project, and the aggregate value of the work planned with Andelyn is material to the Company.
|
|
|